AR107912A1 - Inhibidores de ret - Google Patents

Inhibidores de ret

Info

Publication number
AR107912A1
AR107912A1 ARP170100670A ARP170100670A AR107912A1 AR 107912 A1 AR107912 A1 AR 107912A1 AR P170100670 A ARP170100670 A AR P170100670A AR P170100670 A ARP170100670 A AR P170100670A AR 107912 A1 AR107912 A1 AR 107912A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroalkyl
considered independently
cycloalkyl
alkoxy
Prior art date
Application number
ARP170100670A
Other languages
English (en)
Inventor
Kevin J Wilson
Joseph L Kim
Jason D Brubaker
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of AR107912A1 publication Critical patent/AR107912A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente memoria se describen compuestos que inhiben a RET de tipo silvestre y sus mutantes resistentes, composiciones farmacéuticas que incluyen a dichos compuestos, y métodos para utilizar dichos compuestos y composiciones. Reivindicación 1: Un compuesto que posee la fórmula estructural (1), o una sal del mismo apta para uso farmacéutico, donde: el anillo A es un anillo arilo o heteroarilo; cada uno de X¹ y X², considerado en forma independiente, se selecciona a partir de N y C(R⁶); cada R¹ y cada R⁷, considerado en forma independiente, se selecciona a partir de C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₁₋₆ alcoxi, halo, C₁₋₆ heteroalquilo, cicloalquilo, arilo, heteroarilo, ariloxi, aralquilo, heterociclilo, heterociclilalquilo, nitro, ciano, -C(O)R, -OC(O)R, -C(O)OR, (C₁₋₆ alquilen)-C(O)R, -SR, -S(O)₂R, -S(O)₂-N(R)(R), (C₁₋₆ alquilen)-S(O)₂R, (C₁₋₆ alquilen)-S(O)₂-N(R)(R), -N(R)(R), -C(O)-N(R)(R), -N(R)-C(O)R, -N(R)-C(O)OR, -(C₁₋₆ alquilen)N(R)C(O)R, -N(R)S(O)₂R, y -P(O)(R)(R); donde cada uno de alquilo, alquenilo, alquinilo, alcoxi, heteroalquilo, cicloalquilo, arilo, heteroarilo, ariloxi, aralquilo, heterociclilo, y heterociclilalquilo, considerado en forma independiente, está sustituido con 0 - 5 casos de Rᵃ; o dos R¹ o dos R⁷ tomados en forma conjunta con los átomos de carbono a los que están unidos forman un anillo cicloalquilo o heterociclilo el cual, considerado en forma independiente, está sustituido con 0 - 5 casos de Rᵇ; cada uno de R², R³ᵃ, R³ᵇ, R⁴, R⁸ᵃ y R⁸ᵇ, considerado en forma independiente, se selecciona a partir de hidrógeno, C₁₋₆ alquilo, C₁₋₆ alcoxi, halo, hidroxilo, C₁₋₆ heteroalquilo, y -N(R)(R); donde cada alquilo, alcoxi, y heteroalquilo, considerado en forma independiente, opcionalmente está sustituido con 0 - 5 casos de Rᵃ; cada uno de R⁵ y R⁹, considerado en forma independiente, se selecciona a partir de hidrógeno, C₁₋₆ alquilo, y C₁₋₆ heteroalquilo; donde cada alquilo y heteroalquilo, considerado en forma independiente, opcionalmente está sustituido con 0 - 5 casos de Rᵃ; cada R⁶, considerado en forma independiente, se selecciona a partir de hidrógeno, C₁₋₆ alquilo, C₁₋₆ alcoxi, halo, C₁₋₆ heteroalquilo, y -N(R)(R); donde cada alquilo, alcoxi, y heteroalquilo, considerado en forma independiente, opcionalmente está sustituido con 0 - 5 casos de Rᵃ; cada R, considerado en forma independiente, se selecciona a partir de hidrógeno, hidroxilo, halo, tiol, C₁₋₆ alquilo, C₁₋₆ tioalquilo, C₁₋₆ alcoxi, C₁₋₆ heteroalquilo, cicloalquilo, cicloalquilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo, donde cada uno de alquilo, tioalquilo, alcoxi, heteroalquilo, cicloalquilo, cicloalquilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo, considerado en forma independiente, está sustituido con 0 - 5 casos de Rᵃ, o dos R tomados en forma conjunta con el o los átomos a los que están unidos forman un anillo cicloalquilo o heterociclilo el cual, considerado en forma independiente, está sustituido con 0 - 5 casos de Rᵇ; cada Rᵃ y cada Rᵇ, considerado en forma independiente, se selecciona a partir de C₁₋₆ alquilo, halo, hidroxilo, C₁₋₆ heteroalquilo, C₁₋₆ alcoxi, cicloalquilo, heterociclilo, o ciano, donde cada uno de alquilo, heteroalquilo, alcoxi, cicloalquilo y heterociclilo, considerado en forma independiente, está sustituido con 0 - 5 casos de R’; cada R’, considerado en forma independiente, se selecciona a partir de C₁₋₆ alquilo, C₁₋₆ heteroalquilo, halo, hidroxilo, cicloalquilo o ciano; o dos R’ tomados en forma conjunta con el o los átomos a los que están unidos forman un anillo cicloalquilo o heterociclilo; m es 0, 1, ó 2; y n es 0, 1, 2, ó 3.
ARP170100670A 2016-03-17 2017-03-17 Inhibidores de ret AR107912A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662309748P 2016-03-17 2016-03-17

Publications (1)

Publication Number Publication Date
AR107912A1 true AR107912A1 (es) 2018-06-28

Family

ID=58428429

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100670A AR107912A1 (es) 2016-03-17 2017-03-17 Inhibidores de ret

Country Status (5)

Country Link
US (1) US10183928B2 (es)
AR (1) AR107912A1 (es)
TW (1) TW201738228A (es)
UY (1) UY37155A (es)
WO (1) WO2017161269A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170098A (es) 2010-05-20 2017-07-17 Array Biopharma Inc Compuestos macrociclicos como inhibidores de quinasa trk
RS62233B1 (sr) 2012-07-11 2021-09-30 Blueprint Medicines Corp Inhibitori receptora fibroblast faktora rasta
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RU2706235C2 (ru) 2013-10-17 2019-11-15 Блюпринт Медсинс Корпорейшн Композиции, пригодные для лечения расстройств, связанных с kit
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CA2994819A1 (en) 2015-07-24 2017-02-02 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr
AU2016311426B2 (en) 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
AU2016348402B2 (en) 2015-11-02 2021-05-13 Blueprint Medicines Corporation Inhibitors of RET
EP3377497A1 (en) 2015-11-19 2018-09-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
DK3442977T3 (da) 2016-04-15 2023-10-09 Blueprint Medicines Corp Inhibitorer af activinreceptorlignende kinase
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
WO2018213329A1 (en) 2017-05-15 2018-11-22 Blueprint Medicines Corporation Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN110294745B (zh) * 2018-03-22 2022-04-19 浙江海正药业股份有限公司 五元杂环类衍生物及其制备方法和其在医药上的用途
AU2019247766A1 (en) 2018-04-03 2020-10-15 Blueprint Medicines Corporation RET inhibitor for use in treating cancer having a RET alteration
CN112703014A (zh) 2018-08-10 2021-04-23 缆图药品公司 Egfr突变型癌症的治疗
WO2020035065A1 (zh) * 2018-08-17 2020-02-20 南京明德新药研发有限公司 作为ret抑制剂的吡唑衍生物
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての縮合複素環式化合物
WO2020083332A1 (zh) * 2018-10-24 2020-04-30 南京明德新药研发有限公司 作为ret抑制剂的嘧啶衍生物
WO2020083311A1 (zh) * 2018-10-24 2020-04-30 南京明德新药研发有限公司 作为ret抑制剂的吡嗪衍生物
CN111285875B (zh) * 2018-12-06 2023-02-03 苏州信诺维医药科技股份有限公司 一种杂环化合物、其应用及含其的药物组合物
CN111285882B (zh) * 2018-12-07 2022-12-02 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
CN111484479B (zh) * 2019-01-25 2023-06-13 四川科伦博泰生物医药股份有限公司 氮杂环化合物、包含其的药物组合物及其制备方法和用途
CN111499613B (zh) * 2019-01-31 2023-05-12 浙江海正药业股份有限公司 N-甲酰胺衍生物、其制备方法及其在医药上的用途
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3950688A4 (en) * 2019-04-03 2022-11-30 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory SPIRO DERIVATIVE CONTAINING NITROGEN USED AS A RET INHIBITOR
CN111808077B (zh) * 2019-04-12 2023-05-02 浙江海正药业股份有限公司 哌嗪酰胺衍生物,其制备方法及其在医药上的用途
DK3856341T3 (da) 2019-04-12 2023-12-04 Blueprint Medicines Corp Krystallinske former af (s)-1-(4-fluorphenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amin og fremgangsmåder til fremstilling deraf
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN113135896A (zh) * 2020-01-18 2021-07-20 正大天晴药业集团股份有限公司 作为ret抑制剂的甲基吡唑类衍生物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR121914A1 (es) * 2020-04-27 2022-07-20 Lilly Co Eli Compuestos útiles para inhibir la quinasa ret
CA3197032A1 (en) 2020-11-06 2022-05-12 Eli Lilly And Company Pyrazole derivatives as ret kinase inhibitors
KR20240132251A (ko) 2021-10-22 2024-09-03 유니버시티 오브 휴스턴 시스템 상피 조직의 만성 염증성 손상, 화생, 이형성증 및 암을 치료하기 위한 방법 및 조성물
CN117466901A (zh) * 2022-07-23 2024-01-30 浙江海正药业股份有限公司 哌嗪酰胺衍生物的晶型及其制备方法和用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
CN1668306A (zh) 2002-07-24 2005-09-14 辛辛那提大学 用于治疗与突变的 r e t激酶相关疾病的4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-((吡啶-3-基)嘧啶-2-基基氨)苯基]-苯甲酰胺
US20100047777A1 (en) 2005-05-26 2010-02-25 The Johns Hopkins University Methods for identifying mutations in coding and non-coding dna
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
EP2074118A2 (en) 2007-07-09 2009-07-01 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009014537A1 (en) 2007-07-25 2009-01-29 Hewlett-Packard Company Systems and methods for detecting ink mixing
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
JP2013509444A (ja) 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
CN102811619B (zh) 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
CN103764676A (zh) 2011-08-04 2014-04-30 日本国立癌症研究中心 Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法
AU2012298884B2 (en) 2011-08-23 2017-11-16 Foundation Medicine, Inc. Novel KIF5B-RET fusion molecules and uses thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
RS62233B1 (sr) 2012-07-11 2021-09-30 Blueprint Medicines Corp Inhibitori receptora fibroblast faktora rasta
US20150177246A1 (en) 2012-07-26 2015-06-25 Lsip, Llc Fusion gene of cep55 gene and ret gene
JP6513567B2 (ja) * 2012-09-07 2019-05-15 エクセリクシス, インク. 肺腺癌の治療で使用するためのmet、vegfr、およびretの阻害剤
HUE040055T2 (hu) 2012-09-25 2019-02-28 Chugai Pharmaceutical Co Ltd RET inhibitor
CN104870446B (zh) 2012-11-07 2019-08-13 内尔维阿诺医学科学有限公司 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
JP6186012B2 (ja) 2013-02-25 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
UA115264C2 (uk) 2013-03-15 2017-10-10 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Піридинові похідні як інгібітори реаранжованої у процесі трансфекції (ret) кінази
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
EP3037547A1 (en) 2013-08-20 2016-06-29 National Cancer Center New fusion gene detected in lung cancer
RU2706235C2 (ru) 2013-10-17 2019-11-15 Блюпринт Медсинс Корпорейшн Композиции, пригодные для лечения расстройств, связанных с kit
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
JP6061341B2 (ja) 2013-12-06 2017-01-18 朝日インテック株式会社 ガイドワイヤ
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
JP6538153B2 (ja) 2014-09-10 2019-07-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Rearranged during transfection(ret)阻害剤としての新規な化合物
EP3517526B1 (en) 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
PL3218378T3 (pl) 2014-11-14 2020-10-19 Nerviano Medical Sciences S.R.L. Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CA2994819A1 (en) 2015-07-24 2017-02-02 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr
AU2016311426B2 (en) 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
AU2016348402B2 (en) 2015-11-02 2021-05-13 Blueprint Medicines Corporation Inhibitors of RET
EP3377497A1 (en) 2015-11-19 2018-09-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
DK3442977T3 (da) 2016-04-15 2023-10-09 Blueprint Medicines Corp Inhibitorer af activinreceptorlignende kinase
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors

Also Published As

Publication number Publication date
TW201738228A (zh) 2017-11-01
UY37155A (es) 2017-10-31
US20170267661A1 (en) 2017-09-21
US10183928B2 (en) 2019-01-22
WO2017161269A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
AR107912A1 (es) Inhibidores de ret
AR105836A1 (es) Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk
AR129635A2 (es) Moduladores de tetrahidropiridopirazina de gpr6
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
AR100702A1 (es) Compuestos inhibidores de quinasa de unión tank
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR107973A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj
AR105459A1 (es) Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR094300A1 (es) Derivados de quinolonas
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR090993A1 (es) Pirazol indanil carboxamidas
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR105928A1 (es) Compuesto para usar composiciones que cambian de color
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR095351A1 (es) Inhibidores de histona desacetilasa (hdac)
AR093758A1 (es) Inhibidores de aril lactama quinasa
BR112017019439A2 (pt) inibidores kv1.3 e sua aplicação médica
AR101255A1 (es) Derivados de isoindolinona
ES2571529T3 (es) Nuevos derivados de isoquinolina sustituida
AR103582A1 (es) Ciclopropabenzofuranil-piridopirazindionas
AR109042A1 (es) COMPUESTOS MODULARES DE RORg
AR106548A1 (es) Inhibidores de ret

Legal Events

Date Code Title Description
FB Suspension of granting procedure